Adicet Bio to Present at Upcoming Investor Conferences

Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology firm specializing in allogeneic gamma delta CAR T cell therapies for cancer, announced participation in two upcoming investor conferences.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/07/2022 - 04:10 PM EDT

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in September.

Details of the events are as follows:

H.C. Wainwright 24^th Annual Global Investment Conference, September 12-14, 2022, New York, New York

An on-demand presentation given by Chen Schor, President & CEO will be available beginning Monday, September 12, 2022 at 7:00 A.M. ET

Jefferies Cell and Genetic Medicine Summit, September 29-30, 2022, New York, New York

Chen Schor, President & CEO, will present a corporate overview on Friday, September 30, 2022, at 8:00 A.M. ET.

The live audio webcast of the presentations can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.